SpePharm raises €7mm to fund Savene deal
Executive Summary
European specialty pharmaceuticals company SpePharm Holding BV has raised €7mm ($9.6mm) in Series C money from existing investors TVM Capital, Signet Healthcare, and Paul Capital Healthcare. Funds from the late-stage round will be used for the company's concurrently announced acquisition of worldwide rights (excluding North and South America) to the anthracycline extravasation drug Savene from TopoTarget AS.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice